Table 1. Tumor donor patient characteristics for cachexia avatar lines.
| ID | Age (yr) | Sex | TMN staginga | CA19.9 | BMI (kg/m2) | 6M WL | Avatar hIL-6 (pg/ml) |
|---|---|---|---|---|---|---|---|
| S002 | 84 | M | T3, N1, Mx | 97 | 29.6 | −17.3% | >700 |
| S004 | 84 | F | T3, N1 | 200 | 27.3 | 14.7% | - |
| S005 | 70 | F | T1, N1 | 103 | 26.9 | −10.0% | - |
| S016 | 75 | M | T3, N1 | 2,252 | 21.7 | −11.9% | - |
| S017 | 69 | M | T3, N1 | 25 | 25.6 | −3.2% | 1.94 ± 0.95 |
| S018 | 68 | M | T3, N1, Mx | 544 | 26.6 | −7.2% | - |
| S035 | 65 | M | T2, N1 | 61 | 49.1 | −30.6% | 513.9 ± 152.9 |
| S037 | 82 | F | T3, N0, Mx | 11 | 27 | −4.7% | - |
BMI, body mass index; F, female; hIL, human IL; M, male; 6M WL, 6-mo weight loss.
a
Pathological Tumor Node Metastasis Staging: T1 in pancreas with tumor <2 cm; T2 in pancreas and 2 cm < tumor < 4 cm; T3, beyond pancreas and tumor >4 cm. N0, no regional lymph nodes involved; N1, 1–3 regional lymph nodes involved; Mx, metastasis cannot be measured.